All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Visual abstract | Early guselkumab intervention in psoriasis leads to 'clinical super response': Week 28 results from the phase IIb GUIDE study
By Ella Dixon
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing Week 28 data from the ongoing phase IIIb GUIDE study, investigating the efficacy of guselkumab in patients with moderate-severe plaque psoriasis with either a short disease duration (<2 years) and or a long disease duration (>2 years).1
Key baseline patient characteristics are shown in Table 1. The baseline mean psoriasis area and severity and dermatology life quality index scores were similar between the groups.1
Table 1. Baseline patient characteristics*
|
Characteristic, % unless otherwise stated |
SDD (N = 357) |
LDD (N = 523) |
Overall (N = 880) |
|---|---|---|---|
|
Sex |
|
|
|
|
Female |
31.9 |
27.9 |
29.5 |
|
Male |
68.1 |
72.1 |
70.5 |
|
Age at baseline, years |
|
|
|
|
<45 |
62.5 |
50.5 |
55.3 |
|
45–65 |
30.8 |
42.6 |
37.8 |
|
>65 |
6.7 |
6.9 |
6.8 |
|
Mean disease duration, years |
1.2 |
20.2 |
12.5 |
|
Mean PASI, score |
18.7 |
19.4 |
19.1 |
|
Mean DLQI, score |
19.1 |
18.9 |
19.0 |
|
Patients with prior systemic and/or biologic therapy |
24.6 |
68.3 |
50.6 |
|
DLQI, Dermatology Life Quality Index; LDD, long disease duration; PASI, Psoriasis Area and Severity Index; SDD, short disease duration. *Adapted from Schäkel, et al.1 |
|||
The results from this study have demonstrated that early intervention with guselkumab in patients with psoriasis may lead to a better clinical response, which could lead to overall better long-term outcomes for patients.1
- Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study 2023;37(10):2016-2027. DOI: 10.1111/jdv.19236
More about...
Your opinion matters
6 votes - 84 days left ...
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox